Completed PHASE3 INTERVENTIONAL 3-arm NCT00077623

A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

A Randomized, Controlled, Open-Label, Multi- Center, Parallel-Group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Subcutaneously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysis

Sponsor: Hoffmann-La Roche

Conditions Anemia

Interventions epoetin alfa or beta methoxy polyethylene glycol-epoetin beta (Mircera)

Updated 7 times since 2017 Last updated: Apr 26, 2016 Started: Mar 31, 2004 Primary completion: Sep 30, 2005 Completion: Sep 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Anemia, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 7 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alcorcón, Spain , Bad Hersfeld, Germany , Bangkok, Thailand , Barcelona, Spain , Bayonne, France , Belfast, United Kingdom , Berlin, Germany , Boston, United States , Boulogne, France , Brno, Czechia and 74 more locations